Citi analyst Yigal Nochomovitz lowered the firm’s price target on Rain Oncology to $24 from $29 and keeps a Buy rating on the shares. The analyst updated the model to reflect the Q4 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RAIN:
- Rain Oncology price target lowered to $17 from $18 at Mizuho
- Rain Oncology price target raised to $19 from $12 at H.C. Wainwright
- Rain Oncology reports Q4 EPS (70c), consensus (56c)
- Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
- TipRanks ‘Perfect 10’ List: There’s an Opportunity Brewing in These 2 Stocks